Markus Richard 4

What Happened Markus Richard, Chief Medical Officer of Arcus Biosciences (RCUS), received equity awards on January 23, 2026 consisting of 24,000 shares (reported as acquired) and 96,000 shares reported as a derivative — a total of 120,000 restricted stock units (RSUs). The reported acquisition price for both items was $0.00 (awarded rather than purchased).

Key Details

• Transaction date: January 23, 2026; Form 4 filed January 26, 2026 (within the normal two-business-day reporting window).
• Award amounts and prices: 24,000 shares @ $0.00 (acquired); 96,000 derivative shares @ $0.00 (acquired) — total 120,000 RSUs.
• Vesting: Footnote states these RSUs vest in four equal annual installments beginning December 15, 2026, subject to continued service (F1).
• Shares owned after transaction: Not specified in the provided excerpt; filing notes include unvested RSU amounts (F2).
• Related footnote: There is an additional note (F3) about an option that becomes exercisable in 48 equal monthly installments after January 1, 2026 — this refers to a separate equity award.

Context

• These entries are awards (compensation grants), not open-market purchases or sales; no cash was exchanged at grant ($0.00), and vesting is time-based. Such grants are standard executive compensation and do not by themselves indicate a buy/sell signal.
• The 96,000-share line is reported as a derivative security (RSUs) — RSUs convert to common shares as they vest.